CCEL
NASDAQCryo-Cell International Inc.
Price$3.41+0.01 (+0.29%)
2026-03-042026-06-05
News · 26 weeks14-67%
2025-12-142026-06-07
Mix890d
- Other4(50%)
- SEC Filings3(38%)
- Insider1(13%)
Latest news
25 items- INSIDERVP Finance, CFO Taymans Jill M exercised 7,500 shares at a strike of $3.10, increasing direct ownership by 17% to 52,896 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- SECCryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- PRCryo-Cell Receives Acceptance of Compliance Plan From NYSE AmericanCryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the "NYSE American") has accepted the Company's previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders' deficit as of November 30, 2025, and (ii) net losses in two of its three most recent fiscal years ended November 30, 2023, November 30, 2024 and November 30, 2025. On
- PRCryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood BanksCryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy ("FACT") Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company's latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in
- SECSEC Form 10-Q filed by Cryo-Cell International Inc.10-Q - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- PRCord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial ResultsCryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026. Financial Results Revenue The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million in processing and storage fee revenue, $36,000 in product revenue and approximately $1,400 in public banking revenue compared to $7.87 million in processing and storage fee revenue, $21,000 in product revenue and approximately
- SECCryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- PRCryo-Cell Receives NYSE American Continued Listing NoticeCryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders' deficit as of November 30, 2025, and (ii) net losses in two of its three most recent fiscal years ended November 30,
- SECSEC Form 10-K filed by Cryo-Cell International Inc.10-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- PRCryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue and $130,000 in public banking revenue compared to $31.6 million in processing and storage fee revenue, $68,000 in product revenue and $367,000 in public banking revenue for fiscal 2024. Net (Loss) Income The Company repo
- INSIDERSEC Form 4 filed by Chairman, Co-CEO Portnoy David4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERSEC Form 4 filed by Co-CEO Portnoy Mark L.4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERSEC Form 4 filed by Chief Information Officer Mikulinsky Oleg4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERSEC Form 4 filed by VP Finance, CFO Taymans Jill M4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERChairman, Co-CEO Portnoy David was granted 2,445 shares, increasing direct ownership by 0.13% to 847,629 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERChairman, Co-CEO Portnoy David was granted 3,990 shares, increasing direct ownership by 0.47% to 846,540 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERChairman, Co-CEO Portnoy David was granted 5,540 shares, increasing direct ownership by 0.66% to 842,550 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- SECCryo-Cell International Inc. filed SEC Form 8-K: Other Events8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- INSIDERChairman, Co-CEO Portnoy David was granted 9,666 shares, increasing direct ownership by 1% to 837,010 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- SECCryo-Cell International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- INSIDERSEC Form 4 filed by Director Mizrahi Daniel4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERSEC Form 4 filed by Director Berger Harold D.4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- SECSEC Form 10-Q filed by Cryo-Cell International Inc.10-Q - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- PRCord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial ResultsCryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company", "Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2025. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2025 were $7.83 million compared to $8.07 million for the third quarter of fiscal 2024, a 3% decrease. Net Income The Company reported net income for the three months ended August 31, 2025 of $749,000, or $0.09 per basic share and diluted share, compared to net income of $1.05 million, or $0.13 per basic and diluted share for the three months ended August 31,
- SECSEC Form DEF 14A filed by Cryo-Cell International Inc.DEF 14A - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
CCEL FAQ
6 questionsWhat does Cryo-Cell International Inc. do?
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores...Where does CCEL stock trade?
Cryo-Cell International Inc. (CCEL) is listed on NASDAQ.What sector and industry is CCEL in?
Cryo-Cell International Inc. operates in the Health Care sector, Misc Health and Biotechnology Services industry.When did Cryo-Cell International Inc. go public?
Cryo-Cell International Inc. (CCEL) completed its IPO in 2022.What companies are similar to CCEL?
Notable peers in the same industry include DVA (DaVita Inc.), FMS (Fresenius Medical Care AG), SHC (Sotera Health Company), PGNY (Progyny Inc.), AGL (agilon health inc.). Compare CCEL side-by-side with any of them on Quantisnow.How can I track CCEL on Quantisnow?
Quantisnow aggregates Cryo-Cell International Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CCEL to receive live email and push alerts on every new disclosure.